From Clinical Trials to Clinical Implications: PARP Inhibitor Combinations in Advanced Prostate Cancer

To participate in this activity, please:

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with high disease burden and poor outcomes despite androgen deprivation therapy. This activity by Neeraj Agarwal, MD, provides strategies for germline genetic testing and somatic testing to best inform treatment. Poly (ADP-ribose) polymerase (PARP) inhibitor therapy provides a unique approach to treatment. Dr. Agarwal reviews safety and efficacy findings from recent clinical trials for the 2 PARP inhibitors, olaparib and rucaparib, approved in the United States for mCRPC. He also shares observations regarding PARP inhibitors in combination with other therapies.

Course Credit:

0.50 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2021-06-11
Closes: 2022-06-11

Target Audience:

This activity was developed for medical oncologists and other healthcare professionals involved in the treatment of prostate cancer.

This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc.
  • Neeraj Agarwal, MD

    Professor of Medicine
    Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research
    Co-leader, HCI Experimental Therapeutics Program (CCSG Program)
    Director, Center of Investigational Therapeutics
    Director, Genitourinary Oncology Program
    Salt Lake City, Utah

Learning Objectives

  • Discuss new and emerging data on PARP inhibitors in combination with other therapies for the treatment of advanced PC
  • Identify patients who may benefit from the use of PARP inhibitors combinations for the treatment of advanced PC based on the latest evidence

Faculty Disclosures

Neeraj Agarwal, MD

Advisory Board and Consultant: Astellas, Astra Zeneca, Aveo, Bayer, BMS, Calithera, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Immunomedics, Janssen, MEI Pharma, Merck, Novartis, Pfizer, Seattle Genetic


Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.